newsfilter
← Latest News
Business Wire·

Zura Bio to Participate in Upcoming Investor Conferences

  • Zura Bio Limited management will attend the Leerink Global Healthcare Conference in Miami, FL, on Tuesday, March 10, 2026, including a fireside chat at 2:20 p.m. ET.
  • Zura Bio management will attend the Jefferies Biotech on the Beach Summit in Miami, FL, on Wednesday, March 11, 2026.
  • A live webcast of the Leerink fireside chat will be available on the company website, with a replay accessible for at least 30 days post-event.
  • Zura is a clinical-stage biotechnology company developing dual-pathway antibodies for autoimmune and inflammatory diseases.
  • Lead candidate tibulizumab (ZB-106) is currently under evaluation in two Phase 2 studies: TibuSHIELD for hidradenitis suppurativa & TibuSURE for systemic sclerosis.
  • Product candidates crebankitug (ZB-168) & torudokimab (ZB-880) have completed Phase 1/1b studies & are being evaluated for various autoimmune conditions.